This study enrolls adults with Relapsing Multiple Sclerosis. The purpose of this study is to learn about changes in cognition that happen while being treated with the experimental medication RPC1063 (also known as ozanimod). Read More
- Adults ages 18-65.
- Have at least 5 years since time of RMS diagnosis.
- Have no clinically relevant cardiovascular conditions.
Researchers think the study drug, EPI-7386, may be an effective treatment for metastatic castration-resistant prostate cancer (mCRPC) because the drug works by interfering with the function of the male hormone system that leads to the growth of prostate cancer. Enzalutamide is an androgen receptor inhibitor that works by blocking the action of male hormones (androgens) like testosterone to slow down the growth of prostate cancer. Enzalutamide is approved by the Food & Drug Administration (FDA) and is commonly used as a standard of care option for men with advanced or metastatic castration-resistant prostate cancer. Since EPI-7386 and enzalutamide have not been combined together in humans, we are doing this study to find out whether EPI-7386, in combination with a fixed dose of enzalutamide, compared to standard of care enzalutamide alone, is a safe and effective treatment for men who have mCRPC. Study will be done at Spindrift Clinic location. Read More
1) Males aged 18 years or older
2) Histologically, pathologically, or cytologically confirmed prostate adenocarcinoma
3) Presence of metastatic disease at study entry
4) Naïve to second generation anti-androgens
We are doing this study to learn more about if the combination of medications (durvalumab, tremelimumab and enfortumab vedotin)before and after bladder removal surgery will work and be safe for the treatment of muscle invasive bladder cancer. Also to better understand the disease and associated health problems. Read More
1) Participant must be 18 or older years at the time of screening
2) Histologically or cytologically documented muscle-invasive TCC of the bladder with clinical stage of T2-4aN0-N1M0
3) Medically fit for cystectomy and able to receive neoadjuvant therapy
The purpose of this study is to learn more about the advantages and disadvantages of two brief quitting smoking approaches that could be cost-effective in assisting individuals who suffer from serious mental illness. The first approach is brief advice combined with the use of nicotine gum and patches. The second approach uses an app on your smartphone combined with the use of nicotine gum and patches. Read More
(1) Current DSM-5 diagnosis of schizophrenia, schizoaffective, bipolar, or recurring major depressive disorder;
(2) Functional impairment as indicated by a score of_2 or greater on the WHODAS 8 item version
(3) Smoker as indicated by smoking 5 cigarettes per day over the past 6 months;
(4) Desire to quit smoking as indicated by self-reported serious...
This study is to evaluate the long-term safety and tolerability of daily valbenazine (20, 40, 60, or 80mg) for the treatment of chorea associated with Huntington's Disease (HD) for up to 104 weeks. This study will enroll approximately 120 medically stable male and female subjects with HD who previously completed study drug dosing during the maintenance period as well as the study visit at Week 14 for Study NBI-98854-HD3005. Read More
To participate in this study, subjects must meet the following criteria:
1. Participated in Study NBI-98854-HD3005 and
a) Study drug dosing completion of Study NBI-98854-HD3005, as demonstrated by completed study drug dosing during the dose maintenance period as well as the study visit at Week 14.
b) Early terminated Study NBI-98854-HD3005 for administrative reasons due to COVID-19...
This study will measure the change in blood pressure following 4 months of testosterone therapy with Natesto. A total of 218 subjects with a diagnosis of hypogonadism who successfully complete the 24-hour baseline blood pressure session will be included in the study. The total duration of study will be approximately 4 months. Compensation / Reimbursement to study participants. Read More
1. Male between 18 and 80 years of age, inclusive, with documented onset of
hypogonadism prior to age 65.
2. Serum total testosterone < 300 ng/dL based on 2 consecutive blood samples obtained no
greater than 1-4 weeks apart between 6 and 10 AM following an appropriate washout of
current androgen replacement therapy if not testosterone naive. Historical values from
the past 6 months may be use...
We plan to collect urine samples from patients with Parkinson's Disease, from which we can model the Parkinson's brain. Genetically, the neurons we generate from the urine will match that of the patient donor, making them an ideal way to screen for markers of disease. We will use our urine-derived neurons to assess differences between patient and healthy control cells, as well as a comparison of time-points from individual patients. This study will allow us to gain a clearer understanding of the altered neurochemical state that is so difficult to assess in Parkinson’s patients. Read More
Diagnosis of Parkinson's Disease (or spousal control), either with or without resting tremor
Aged between 40 and 99 years of age
Absence of renal disease
This study will look how safe and effective the investigational drug firibastat (not yet approved for market) is. On top of your current medication, you will receive either firibastat(half of all participants) or placebo (half of all participants) for the first 12-weeks followed by open-label study treatment with firibastat for 24 or 36-weeks; the placebo looks exactly the same as the investigational drug, but contains no active medicine. The group you are in will be selected at random. The study medication and placebo will be taken by mouth once daily. Read More
Must be >=18 years of age
Diagnosis of primary hypertension (high blood pressure) for at least 6 months prior to screening
Currently treated with at least 2 high blood pressure medications
Have a systolic office blood pressure between 140 mmHg and 179 mmHg at screening
Have a systolic home blood pressure with a mean 135 mmHg after the run-in period
This study's primary objective is to assess the effects of dehydration followed by rapid rehydration on weightlifting. We are recruiting males and females aged 18-39 who are recreationally trained for barbell sports and have at least 6 months of experience with Olympic lifting. Participants will spend 12 hours in the lab on UB's South Campus across 5 separate visits. Read More
- Ages 18-39
- Recreationally trained for barbell sports
- Have at least 6 months of experience with Olympic lifting
We are studying metabolism while marching with a heavy military backpack in dry and humid environments. Your first 3 visits will consist of completing questionnaires, a health screening & a series of exercises. During the following 6 visits you will perform treadmill walking while carrying a heavy military backpack. Read More
Healthy, physically active females (18-39 y) who pass the Occupational Physical Assessment Test (OPAT) with at least a gray score in each task (significant job requirement) will be eligible to participate. To ensure that extraneous variables do not impact study results, subjects will be excluded from participation for any of the following reasons:
- History of cardiovascular, metabolic, resp...